INO Stock — Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc (INO)

Updated October 16, 2026.

INO is a Stock. Total return is -99.9% over the past 27.9 years, 1045.8 points behind SPY at 945.9%.

Inovio Pharmaceuticals is a biotechnology company developing DNA-based medicines to treat diseases associated with human papillomavirus, cancer, and infectious diseases, including vaccine candidates for COVID-19, Ebola, and HIV currently in clinical trials. The company does not currently distribute to shareholders. Inovio appeals to investors seeking exposure to early-stage biotech development with tolerance for clinical trial risk and long time horizons before potential commercialization.

INO performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 27.9 years, 1045.8 points behind SPY at 945.9%. Over the past year its total return — price change plus distributions reinvested — is -59.7%. Its deepest 1-year drawdown was 74.6%.

INO key facts

Asset type

Stock

Asset class

Equity

Inception date

12/08/1998

Distribution frequency

None

Last close

$0.99 (as of 2026-10-16)

Market cap

$102,373,883

Average volume

2050682.0

Ex-dividend date

09/28/2017

Payment date

10/16/2017

Beta

1.611

Payout ratio

0.0%

Forward P/E

16.5837

EPS

$-0.95

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 74.6%.

Who may consider INO — and who may not

It is a weaker fit for investors who need monthly cash flow (INO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on INO

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions